Search - tctmd.com

Displaying 121 - 140 of 204

Sort: Relevancy | Date

News Daily News

ROCKET AF Investigators: Problems With Warfarin Monitoring Device Did Not Skew Results

February 04, 2016

News Daily News

Investigadores del ROCKET AF: Los Problemas con un Dispositivo para la Monitorización de la Warfarina No Sesgaron los Resultados

February 04, 2016

News Industry News

Real-World Data Confirms Safety and Efficacy Profile of XARELTO®, With Shorter Hospital Stays, for the Treatment of Deep Vein Thrombosis

December 07, 2015

News Conference News AHA 2015

AHA 2015 Promises Appropriate PCI, Ticagrelor Tolerance, Outcomes With IVUS, and More

November 05, 2015

News Daily News

首个 NOAC 逆转剂 Idarucizumab 获批；不太可能耽误介入治疗

October 26, 2015

News Daily News

First NOAC Antidote, Idarucizumab, Approved; Likely Won’t Hold Up Interventions

October 26, 2015

News Daily News

Aprobado el Idarucizumab, Primer Antídoto de NOAC; El Deseo es no Demorar las Intervenciones

October 26, 2015

News Industry News

Portola Pharmaceuticals Announces Second Part of Phase 3 ANNEXA(TM)-R Study: Andexanet Alfa and Rivaroxaban Meets Primary and Secondary Endpoints

September 16, 2015

News Industry News

Daiichi Sankyo gets EU OK for Lixiana anticoagulant

June 26, 2015

News Industry News

Patients Undergoing Catheter Ablation Presented at Heart Rhythm 2015

May 15, 2015

News Daily News

真实案例研究凸显新抗凝血剂的胃肠道出血风险

May 04, 2015

News Daily News

Real-World Studies Highlight GI Bleeding Concerns With Newer Anticoagulants

May 04, 2015

News Daily News

Estudios del Mundo Exponen que Preocupan las Hemorragias Gastrointestinales secundarias a los Nuevos Anticoagulantes

May 04, 2015

Comparative Risk of GI Bleeding With Dabigatran, Rivaroxaban, and Warfarin: Population-Based Study

Presentation

Comparative Risk of GI Bleeding With Dabigatran, Rivaroxaban, and Warfarin: Population-Based Study

Presenter: Neena S. Abraham

May 01, 2015

News Daily News

ISAR-TRIPLE Published: No Net Gain for 6 Weeks vs 6 Months of Triple Therapy

April 29, 2015

News Daily News

ISAR-TRIPLE Publicado: No hay Beneficio Neto durante 6 Semanas frente a 6 Meses a Tratamiento Triple

April 29, 2015

Uso responsable de Rivaroxabán en prevención secundaria después de un SCA:Casos clínicos_

Presentation CADECI 2015

Uso responsable de Rivaroxabán en prevención secundaria después de un SCA:Casos clínicos_

Presenter: DR. JOSE LUIS LEIVA PONS

February 20, 2015

Uso responsable de rivaroxabán en prevención secundaria tras un SICA

Presentation CADECI 2015

Uso responsable de rivaroxabán en prevención secundaria tras un SICA

Presenter: Dr. Carlos Felipe Barrera-Ram?rez

February 19, 2015

News Daily News

心力衰竭会使ACS后的结果恶化，阿哌沙班不能带来益处

January 28, 2015

News Daily News

La IC Empeora los Resultados Post-SCA No observándose Beneficio alguno con Apixaban

January 28, 2015

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.